Reviewer's report

Title: Novel BRCA2 pathogenic variant c.5219T>G p.(Leu1740Ter) in a consanguineous Senegalese family with hereditary breast cancer

Version: 0 Date: 24 Jan 2019

Reviewer: Sara Gutiérrez-Enríquez

Reviewer's report:

Minor essential editions:

-Line 130: The legend of Table 1 needs more explanation to be comprehensive and self-explaining. A suggestion: BRCA2 variants identified in the index case and classified as benign by expert panel in ClinVar (RefSeq NM_000059.3).

-Lines 145-147: "Inherited breast cancer risk is associated to two high penetrance susceptibility genes, BRCA1 and BRCA2 while other minor genes have also been linked to the disease (including PALB2, P53 and 147 PTEN)"

What do the authors mean with "minor" genes?

Suggestion: Inherited breast cancer risk is mainly associated with two high penetrance susceptibility genes, BRCA1 and BRCA2, yet pathogenic variants in other genes including PALB2, TP53 and PTEN have also been linked with high risk of breast cancer.

-Lines 397-400. Figure Legends:

For index case is sufficient the arrow symbol. The P letter accompanying the arrow is unnecessary. The drawing of the arrow is too big! Please decrease its size.

For individuals with pathogenic variant the letter E is not necessary. It is sufficient a + symbol.

Please add all the results for each of the 19 relatives analysed, adding a + (positive) symbol for those individuals who were carriers of the BRCA2 pathogenic variant and, a - (negative) symbol for individuals were non-carriers of the variant.

All manuscript:

-The HGVS nomenclature recommends that variant prediction effect in protein be described in parentheses.

The authors have written: e.g. (p.Trp194Ter)
Only the prediction of the effect should be in parentheses, so that the letter p. is left out of parentheses, i.e.: p.(Trp194Ter).

Please change it all along manuscript.

Minor discretionary editions:
-Line 107: add number of supplementary table, i.e. supplementary table 1
-Line 166: Table 3 legend: please add that pathogenic variants are reported in ClinVar:
Table 3: Reported pathogenic variants in ClinVar, at nucleotide 5219 or surrounding this position of the
BRCA2 gene (RefSeq NM_000059.3).

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable
**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal